Alberto Bardelli,Federica Di Nicolantonio,Sabrina Arena
申请号：
US13132737
公开号：
US20120115896A1
申请日:
2008.12.03
申请国别(地区):
US
年份:
2012
代理人:
摘要：
Isogenic human cell lines comprising at least one mutated cancer allele under the control of the cell line endogenous promoter, which corresponds to the wild-type cancer allele promoter are disclosed, as well as an in vitro process for determining sensitivity/resistance of a patient suffering from a tumor to a pharmacological agent comprising the following steps: a) identifying at least one mutated cancer allele in a tissue affected by a tumor of said patient b) providing an isogenic human cell line representative of the tissue, wherein the cell line comprises at least the identified mutated cancer allele, which is under the control of the cell line endogenous promoter corresponding to the wild-type cancer allele promoter c) putting in contact said cell line with the pharmacological agent d) determining a variation of proliferation, apoptosis or cytotoxicity of the cell line in presence of the pharmacological agent wherein the variation of proliferation, apoptosis car cytotoxicity indicative of the sensitivity/resistance of the patient tumor to the pharmacological agent.
